Maxim Group reiterated their buy rating on shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) in a research report released on Monday. The firm currently has a $15.00 target price on the stock.

A number of other research firms have also commented on AVXL. Zacks Investment Research lowered shares of Anavex Life Sciences Corp. from a buy rating to a hold rating in a research report on Tuesday, July 12th. FBR & Co reissued an outperform rating and issued a $10.00 price target on shares of Anavex Life Sciences Corp. in a research report on Wednesday, October 5th.

Anavex Life Sciences Corp. (NASDAQ:AVXL) traded down 4.72% on Monday, reaching $3.23. 152,379 shares of the company’s stock were exchanged. Anavex Life Sciences Corp. has a 12 month low of $2.43 and a 12 month high of $14.84. The firm has a 50 day moving average of $3.13 and a 200 day moving average of $4.49. The stock’s market capitalization is $115.34 million.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.03. Equities analysts predict that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in Anavex Life Sciences Corp. by 47.2% in the first quarter. Geode Capital Management LLC now owns 179,549 shares of the company’s stock worth $879,000 after buying an additional 57,572 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new stake in Anavex Life Sciences Corp. during the second quarter worth $313,000. State Street Corp increased its stake in Anavex Life Sciences Corp. by 349.4% in the second quarter. State Street Corp now owns 88,972 shares of the company’s stock worth $544,000 after buying an additional 69,172 shares in the last quarter. Rhumbline Advisers acquired a new stake in Anavex Life Sciences Corp. during the second quarter worth $192,000. Finally, Teachers Advisors Inc. acquired a new stake in Anavex Life Sciences Corp. during the second quarter worth $314,000. Hedge funds and other institutional investors own 10.72% of the company’s stock.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

5 Day Chart for NASDAQ:AVXL

Receive News & Stock Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related stocks with our FREE daily email newsletter.